Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 308

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers

Open access
Derks, Sarah, Liao, Xiaoyun, Chiaravalli, Anna M., Xu, Xinsen, Camargo, M. Constanza, Solcia, Enrico, Sessa, Fausto, Fleitas, Tania, Freeman, Gordon J., Rodig, Scott J., Rabkin, Charles S., Bass, Adam J.·2016·Oncotarget

Abstract

// Sarah Derks 1, 2 , Xiaoyun Liao 1, 3, * , Anna M. Chiaravalli 4, * , Xinsen Xu 1 , M. Constanza Camargo 5 , Enrico Solcia 6 , Fausto Sessa 4 , Tania Fleitas 1, 7 , Gordon J. Freeman 1 , Scott J. Rodig 3, 8 , Charles S. Rabkin 5 , Adam J. Bass 1, 9 1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA 2 Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands 3 The Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA 4 Department of Pathology, Ospedale di Circolo, Varese, Italy 5 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA 6 Department of Molecular Medicine, University of Pavia and Policlinico S. Matteo, Pavia, Italy 7 Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain 8 Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, USA 9 Cancer Program, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA * These authors are contributed equally to this work Correspondence to: Adam J. Bass, email: adam_bass@dfci.harvard.edu Keywords: EBV-infected gastric cancers, MSI gastric cancer, PD-L1, PD-1 inhibitors Received: February 01, 2016 Accepted: April 10, 2016 Published: April 28, 2016 ABSTRACT Gastric cancer (GC) is a deadly disease with limited treatment options. Recent studies with PD-1 inhibition have shown promising results in GC, but key questions remain regarding which GC subclass may respond best. In other cancers, expression of the PD-1 ligand PD-L1 has been shown to identify cancers with greater likelihood of response to PD-1 blockade. We here show with immunohistochemistry that Epstein-Barr Virus (EBV)+ GCs ( n = 32) have robust PD-L1 expression not seen in other GCs. In EBV+ GC, we observed PD-L1 staining in tumor cells in 50% (16/32) and immune cells in 94% (30/32) of cases. Among EBV-negative GCs, PD-L1 expression within tumors cells was observed only in cases with microsatellite instability (MSI), although 35% of EBV-/MSS GCs possessed PD-L1 expression of inflammatory cells. Moreover, distinct classes of GC showed different patterns of PD-L1+ immune cell infiltrations. In both EBV+ and MSI tumors, PD-L1+ inflammatory cells were observed to infiltrate the tumor. By contrast, such cells remained at the tumor border of EBV-/MSS GCs. Consistent with these findings, we utilized gene expression profiling of GCs from The Cancer Genome Atlas study to demonstrate that an interferon-γ driven gene signature, an additional proposed marker of sensitivity to PD-1 therapy, were enriched in EBV+ and MSI GC. These data suggest that patients with EBV+ and MSI GC may have greater likelihood of response to PD-1 blockade and that EBV and MSI status should be evaluated as variables in clinical trials of these emerging inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.9076

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 308

Metadata

Authors
Derks, S., Liao, X., Chiaravalli, A. M., Xu, X., Camargo, M. C., Solcia, E., Sessa, F., Fleitas, T., Freeman, G. J., Rodig, S. J., Rabkin, C. S., & Bass, A. J.
Venue
Oncotarget
Published
2016-04-28
Volume
7
Issue
22
Pages
32925-32932
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2342599605
Cited by
308
References
22
FWCI
19.16
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.